Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy-Reference-Cited by-同舟云学术

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

Published:2013-11-18 Issue:47 Volume:33 Page:5405-5414
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Leconet W,Larbouret C,Chardès T,Thomas G,Neiveyans M,Busson M,Jarlier M,Radosevic-Robin N,Pugnière M,Bernex F,Penault-Llorca F,Pasquet J-M,Pèlegrin A,Robert B

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2013487.pdf

Reference40 articles.

1. Nelson NJ . Pancreatic Cancer Research Matures. J Natl Cancer Inst 2007; 99: 1432–1434.

2. Beck A, Wurch T, Bailly C, Corvaia N . Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10: 345–352.

3. Vanneman M, Dranoff G . Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12: 237–251.

4. Kim EJ, Simeone DM . Advances in pancreatic cancer. Curr Opin Gastroenterol 2011; 27: 460–466.

5. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801–1806.

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hallmarks of pancreatic cancer: spotlight on TAM receptors;eBioMedicine;2024-09

2. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors;Frontiers in Immunology;2024-03-06

3. Structure-activity relationship study of 1,6-naphthyridinone derivatives as selective type II AXL inhibitors with potent antitumor efficacy;European Journal of Medicinal Chemistry;2024-02

4. Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells;Blood;2023-10-26

5. Fc-engineered monoclonal antibodies to reduce off-target liver uptake;EJNMMI Research;2023-09-11